Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes (DEMAND)

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01265836
First received: December 14, 2010
Last updated: April 11, 2011
Last verified: April 2011
  Purpose

The purpose of this study is to establish the proportion of patients on lipid-lowering pharmacological treatment (statin or combination) reaching the LDL-C goals according to the updated 2004 National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) guidelines.


Condition
Dyslipidemia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Dyslipidemia Treatment in Thailand and Cardiovascular Outcomes

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The number (#) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines. [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • The percent (%) of subjects achieving the LDL-C goals according to updated 2004 NCEP ATP III guidelines. [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The number of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • The number of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • The number of the secondary event rate cardiovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 year [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • The percentage of subjects achieving the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for several subject subsets [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • The percent of the secondary event rate of cerebrovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 [ Time Frame: 1 year ] [ Designated as safety issue: No ]
  • The percent of the secondary event rate cardiovascular patients on lipid-lowering pharmacological treatment (statin or combination) who reaching and non-reaching the LDL-C goals according to the updated 2004 NCEP ATP III guidelines for 1 year [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 1064
Study Start Date: March 2011
Estimated Study Completion Date: March 2013
Estimated Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)

Detailed Description:

MC MD

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
  1. Provision of subject informed consent
  2. Female or male aged = 18 years
  3. Patients eligible for treatment of dyslipidemia with statins, according to the current guidelines NCEP ATPIII about Dyslipidemias and Atherosclerosis Prevention.
  4. Receiving lipid-lowering drug treatment for at least 15 days.
Criteria

Inclusion Criteria:

  • Provision of subject informed consent, Female or male aged = 18 years
  • Patients eligible for treatment of dyslipidemia with statins, according to the current guidelines NCEP ATPIII about Dyslipidemias and Atherosclerosis Prevention Receiving lipid-lowering drug treatment for at least 15 days.

Exclusion Criteria:

  • Involvement in the planning and conduct of the study (applies to either AstraZeneca staff or staff at the study site).
  • Previous enrolment or randomisation of treatment in the present study
  • Participation in a clinical study during the last 90 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01265836

Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Apichard Sukonthasarn, Prof.M.D. Maharaj Nakorn Chiangmai Hospital Cardiovascular division, Department of Internal Medicine, Faculty of Medicine, Chiangmai University
  More Information

No publications provided

Responsible Party: Marketing Company Medical Director, AstraZeneca
ClinicalTrials.gov Identifier: NCT01265836     History of Changes
Other Study ID Numbers: NIS-CTH-DUM-2010/1
Study First Received: December 14, 2010
Last Updated: April 11, 2011
Health Authority: Thailand: Ministry of Public Health

Keywords provided by AstraZeneca:
Dyslipidemia Treatment and Cardiovascular Outcomes

Additional relevant MeSH terms:
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases

ClinicalTrials.gov processed this record on September 30, 2014